- Home
- FluxMPS™ Minimum Essential Medium (MEM), Low Glucose & 25mM HEPES w/o L-Glutamine, Sodium Bicarbonate: 1X Liquid
FluxMPS™ Minimum Essential Medium (MEM), Low Glucose & 25mM HEPES w/o L-Glutamine, Sodium Bicarbonate: 1X Liquid
FluxMPS™ Minimum Essential Medium (MEM), Low Glucose & 25mM HEPES w/o L-Glutamine, Sodium Bicarbonate: 1X Liquid is a Microfluidics Suitable, quadruple-stage ultra-filtered (0.1 µm ×2 + 0.04 µm ×2) cell culture medium engineered for organ-on-a-chip (OoC), tissue-on-a-chip (ToC), and microphysiological system (MPS) applications. This bicarbonate-free, 25 mM HEPES-buffered, low-glucose MEM formulation ships without L-glutamine and without sodium bicarbonate, giving full control over nitrogen-source supplementation and buffering behavior. A quadruple-stage train (0.1 µm ×2 + 0.04 µm ×2) reaches a 0.04 µm final cut-off, five times finer than the 0.22 µm membranes used for conventional sterile filtration.
- Quadruple-stage nano-filtration to a 0.04 µm final pore size (0.1 µm ×2 + 0.04 µm ×2), reducing particulate load well below conventional 0.22 µm-filtered media
- Endotoxin release specification: < 0.05 EU/mL (LAL, USP <85> BET), tested per manufacturing batch
- MEM base formulation, Low Glucose (1.0 g/L) with Sodium Pyruvate (110 mg/L); pH 7.4 (USP <791>)
- 25 mM HEPES buffering; formulated without L-glutamine and without sodium bicarbonate for reduced CO2 dependence
- Manufactured under an ISO 13485:2016 quality management system with ISO Class 5 aseptic fill & finish
- Prepared with Ultrapure Type 1 water (18.2 MΩ·cm) throughout formulation and dilution
- Custom pH, glucose concentration, salts, HEPES, and nutrient composition available on request — contact support@diagnocine.com
- Glucose1000 mg/L (1.0 g/L)
- L-GlutamineNot added — supplement as needed
- Sodium Pyruvate110 mg/L
- HEPES5958 mg/L (25 mM)
- pH (USP <791>)7.4
- Osmolality (USP <785>)See CoA
- Endotoxin (USP <85>)< 0.05 EU/mL
- Filtration0.1 µm ×2 + 0.04 µm ×2 (Quadruple-stage)
- Storage2–8°C, protect from light
- Shelf Life12 months from date of manufacture, unopened
Engineered where standard media fails
Conventional 0.22 µm-filtered media carry mycoplasma-sized particulates (0.2–0.3 µm), subvisible debris, and lot-to-lot endotoxin variation that accumulate inside microchannels — corrupting biosensor readings, stressing sensitive primary cultures, and shortening device lifetimes. FluxMPS™ is built to address these failure modes at the filtration stage.
Microchannel-safe purity
0.04 µm final filter retains particles to sub-mycoplasma size; USP <788> Method 1 (light obscuration) particulate compliance verified per lot.
Total metabolic control
Defined low-glucose, glutamine-free, bicarbonate-free base gives researchers full control over carbon source and buffering for metabolic flux and Warburg-related studies.
Ultrapure-grade water
Prepared with Type 1 water (18.2 MΩ·cm resistivity), controlled for trace metals and organic carbon (TOC) to minimize contribution to assay background.
Low background for imaging
Quadruple-stage filtration maintains an ultra-low particulate baseline that supports confocal microscopy, live-cell biosensor integration, and TEER measurements.
Rich, stable nutrient profile
Micro-batch precision locks in amino acid and vitamin concentrations for lot-to-lot reproducibility in long-term perfusion studies.
Customization on demand
pH, glucose, salts, HEPES, and full nutrient composition available on request. Contact support@diagnocine.com.
Quadruple-stage filtration system
FluxMPS™ Minimum Essential Medium (MEM), Low Glucose & 25mM HEPES w/o L-Glutamine, Sodium Bicarbonate: 1X Liquid is processed through a four-stage serial filtration train reaching a 0.04 µm final pore size — two dedicated prefilter + final-filter pairs run in series, retaining mycoplasma-scale and subvisible particulates that 0.22 µm filtration does not address.
-
1
0.1 µm Prefiltration I
Removes large particulates, cell debris, and protein aggregates; protects the first 0.04 µm cartridge.
-
2
0.04 µm Final filtration I
First 0.04 µm pass; retains sub-micron particulates and mycoplasma-scale (0.2–0.3 µm) material not captured by standard 0.22 µm filtration.
-
3
0.1 µm Prefiltration II
Second dedicated prefilter, protecting the second 0.04 µm cartridge and providing redundancy against upstream breakthrough.
-
4
0.04 µm Final filtration II — Polish
Ultimate polishing filter; aseptic fill & finish performed in an ISO Class 5 laminar-flow workstation.
Performance vs. conventional media
Two prefilter + final-filter pairs reaching a 0.04 µm final pore size deliver approximately 5× cleaner media by particulate count compared to single-pass 0.22 µm filtration, with USP <788> Method 1 compliance verified on every lot.
© Diagnocine® — DCP-MEMH-QBN1X
Designed for next-generation cell culture platforms
FluxMPS™ Minimum Essential Medium (MEM), Low Glucose & 25mM HEPES w/o L-Glutamine, Sodium Bicarbonate: 1X Liquid is suited to organ-on-a-chip, metabolic research, live-cell imaging, and primary cell models where particulate load and endotoxin variability must be minimized.
Automated Bioreactors & Robotics
An optional 0.01 µm (10 nm) ultra nano-filtered MPS Grade variant of this formulation is available for automated bioreactor and robotic perfusion systems requiring the ultimate particulate exclusion.
- Total Particulate Exclusion: 10 nm filtration for nanoscale valve and sensor protection
- Valve & Sensor Protection: prevents particulate-induced blockage in precision fluidic systems
- Extended Perfusion Stability: maintains flow rate consistency across multi-week automated runs
Inquiry Required: Contact support@diagnocine.com to request the 0.01 µm MPS Grade formulation.
Micro Physiological System (MPS) & Chip
Ultra-filtered formulation reduces the particulate load that drives microchannel clogging and preserves laminar flow integrity.
Warburg Effect & Metabolic Research
Defined low-glucose base and a controlled endotoxin specification support metabolic flux analysis in tumor cell models.
iPSC-Derived Models
Ultra-filtered formulation supports sensitive iPSC differentiation protocols where endotoxin variability can drive off-target effects.
Endothelial & Primary Cells
Microchannel-safe purity supports maintenance of endothelial barrier integrity and stable TEER baselines.
Metabolic Flux Analysis
Defined glucose and pyruvate concentrations support controlled isotope tracing and metabolic flux workflows. Not compatible with Agilent Seahorse XF assays, which require bicarbonate-free, phenol red-free medium.
Microscopy & Optical Sensing
Ultra-low particulate load from 0.04 µm final filtration supports confocal imaging and biosensor integration in microfluidic culture systems.
Lot-release quality parameters
Every production lot of FluxMPS™ Minimum Essential Medium (MEM), Low Glucose & 25mM HEPES w/o L-Glutamine, Sodium Bicarbonate: 1X Liquid undergoes the complete quality-release battery below before shipment.
Available pack sizes: 500 mL, 1000 mL.
| Parameter | Specification |
|---|---|
| Formulation | MEM, Low Glucose, 25 mM HEPES, w/o L-Glutamine, w/o Sodium Bicarbonate, Phenol Red present, Calcium & Magnesium salts, Sodium Pyruvate |
| Appearance | Orange-to-red colored, clear solution |
| pH USP <791> | 7.4 |
| Osmolality USP <785> | See CoA |
| Glucose | 1000 mg/L (1.0 g/L) |
| L-Glutamine | Not added — supplement as needed |
| Sodium Pyruvate | 110 mg/L |
| Phenol Red | 11 mg/L (present) |
| Parameter | Specification |
|---|---|
| Endotoxin USP <85> BET | < 0.05 EU/mL |
| Sterility USP <71> | No growth after 14 days |
| Mycoplasma | 0.1 µm mycoplasma-retentive filtration (not tested per lot) |
| Particulate ≥10 µm USP <788> Method 1 | Compliant |
| Particulate ≥25 µm USP <788> Method 1 | Compliant |
| Water Purity | Ultrapure Type 1, 18.2 MΩ·cm |
| Manufacturing std. ISO 13485 | ISO 13485:2016 |
| Fill environment | ISO Class 5 (Class 100) |
| Parameter | Specification |
|---|---|
| Storage temperature | 2–8°C, protected from light |
| Freeze-thaw | Not recommended |
| Shelf life | 12 months from date of manufacture, unopened |
| Shipping condition | Cold pack |
| CO2 requirement | HEPES-buffered; reduced CO2 dependence (validate per cell line) |
| Parameter | Specification |
|---|---|
| Raw material grade | Cell culture / reagent grade |
| Traceability | Full lot documentation, CoA available |
| Manufacturing QMS | ISO 13485:2016 certified |
| UNSPSC | 41116155 · Molecular biology and cell culture growth media · UNv260801 |
| Regulatory alignment | 21 CFR Part 820 (QMSR) aligned |
| Production method | Micro-batch precision manufacturing |
| Intended use | For Research Use Only (RUO) |
Full composition (mg/L)
Complete formulation with CAS numbers, reproduced from manufacturer specification. Total: 29 components across 4 categories. Custom compositions available on request.
| Component | CAS Number | mg/L |
|---|---|---|
| INORGANIC SALTS | ||
| Calcium chloride dihydrate | 10035-04-8 | 265.000 |
| Magnesium sulfate anhydrous | 7487-88-9 | 97.720 |
| Potassium chloride | 7447-40-7 | 400.000 |
| Sodium chloride | 7647-14-5 | 6800.00 |
| Sodium phosphate dibasic anhydrous | 7558-79-4 | 122.000 |
| Component | CAS Number | mg/L |
|---|---|---|
| AMINO ACIDS | ||
| L-Arginine hydrochloride | 1119-34-2 | 126.000 |
| L-Cystine dihydrochloride | 30189-89-0 | 31.300 |
| L-Histidine hydrochloride monohydrate | 5934-29-2 | 42.000 |
| L-Isoleucine | 73-32-5 | 52.000 |
| L-Leucine | 61-90-5 | 52.000 |
| L-Lysine hydrochloride | 657-27-2 | 72.500 |
| L-Methionine | 63-68-3 | 15.000 |
| L-Phenylalanine | 63-91-2 | 32.000 |
| L-Threonine | 72-19-5 | 48.000 |
| L-Tryptophan | 73-22-3 | 10.000 |
| L-Tyrosine disodium salt | 69847-45-6 | 51.900 |
| L-Valine | 72-18-4 | 46.000 |
| Component | CAS Number | mg/L |
|---|---|---|
| VITAMINS | ||
| Choline chloride | 67-48-1 | 1.000 |
| D-Ca-Pantothenate | 137-08-6 | 1.000 |
| Folic acid | 59-30-3 | 1.000 |
| Niacinamide | 98-92-0 | 1.000 |
| Pyridoxine hydrochloride | 58-56-0 | 1.000 |
| Riboflavin | 83-88-5 | 0.100 |
| Thiamine hydrochloride | 67-03-8 | 1.000 |
| i-Inositol | 87-89-8 | 2.000 |
| OTHERS | ||
| D-Glucose | 50-99-7 | 1000.000 |
| HEPES | 7365-45-9 | 5958.000 |
| Phenol red sodium salt | 34487-61-1 | 11.000 |
| Sodium Pyruvate | 113-24-6 | 110.000 |
ISO 13485:2016 manufacturing & compliance
Manufactured under ISO 13485:2016 QMS with final packaging, testing, and customization at Diagnocine Precision in Totowa, New Jersey, USA.
ISO 13485:2016 QMS
Full quality management system certification covering manufacturing, testing, and release for every production lot.
Ultrapure Type 1 Water
All media prepared with 18.2 MΩ·cm resistivity water, controlled for trace metals and organic carbon (TOC).
ISO Class 5 Fill & Finish
Aseptic filling in a validated ISO Class 5 laminar-flow workstation; 21 CFR Part 820 (QMSR) aligned.
Micro-Batch Precision
Small-batch manufacturing supports lot-to-lot nutrient consistency for reproducible perfusion studies.
Endotoxin — USP <85> BET
LAL assay on every manufacturing batch. Release specification: < 0.05 EU/mL.
Particulate — USP <788> Method 1
Light obscuration particle count confirms ≥10 µm and ≥25 µm compliance per lot.
Osmolality — USP <785>
Freezing-point osmometry per USP <785>. Result: See CoA.
Documentation — CoA & Full Lot Records
Certificate of Analysis with full QC panel, traceability, and release signatures for every lot.
- Endotoxin — LAL assay, USP <85> Bacterial Endotoxins Test; assay sensitivity 0.005 EU/mL; release specification < 0.05 EU/mL
- pH, osmolality, conductivity, appearance and clarity
- Sterility
How DCP-MEMH-QBN1X (FluxMPS™) compares
Side-by-side comparison against conventional 0.22 µm-filtered alternatives of the same base formulation, and against published supplier endotoxin specifications.
| Parameter | DCP-MEMH-QBN1X (FluxMPS™) | Conventional MEM (0.22 µm) | Standard MEM alternative |
|---|---|---|---|
| Grade | Microfluidics Suitable (0.04 µm) | Standard grade (0.22 µm) | Standard grade (0.22 µm) |
| Base Formulation | MEM, Low Glucose, 25 mM HEPES, w/o L-Glutamine, w/o Sodium Bicarbonate | MEM Standard | MEM Equivalent |
| Final filtration pore size | 0.04 µm | 0.22 µm | 0.22 µm |
| Number of filtration stages | 4 stages | 1 stage | 1–2 stages |
| Mycoplasma-retentive filtration | check_circle | cancel | cancel |
| Endotoxin (release specification) | FluxMPS™ — < 0.05 EU/mL | Corning classical liquid media — < 0.25 EU/mL Sigma-Aldrich DMEM complete medium — ≤ 2 EU/mL Gibco classical DMEM — Not specified (recorded per lot) |
|
| USP particulate compliance | check_circle USP <788> Method 1 | cancel | cancel |
| Water quality | Ultrapure Type 1 (18.2 MΩ·cm) | Purified water | Purified water |
| Manufacturing QMS | ISO 13485:2016 | Variable | Variable |
| Microfluidic channel compatibility | check_circle Validated | cancel Risk of clogging | cancel Risk of clogging |
| Custom formulation | check_circle On request | cancel | Limited |
Comparison figures from published supplier specifications, accessed 2026-09-02. Suppliers that publish no numeric endotoxin specification are shown as "Not specified".
Frequently asked questions
Common questions about FluxMPS™ Minimum Essential Medium (MEM), Low Glucose & 25mM HEPES w/o L-Glutamine, Sodium Bicarbonate: 1X Liquid and Microfluidics Suitable cell culture media.
Supporting literature
Peer-reviewed publications supporting Microfluidics Suitable ultra-filtered media and microfluidic cell culture applications.
- Huh D et al. (2010). Reconstituting organ-level lung functions on a chip. Science, 328(5986), 1662–1668. doi:10.1126/science.1188302
- Bhatia SN & Ingber DE (2014). Microfluidic organs-on-chips. Nature Biotechnology, 32(8), 760–772. doi:10.1038/nbt.2989
- Eagle H (1959). Amino acid metabolism in mammalian cell cultures. Science, 130(3373), 432–437. doi:10.1126/science.130.3373.432
- Bhattacharya S et al. (2018). Challenges in maintaining cell viability during microfluidic experiments. Electrophoresis, 39(7), 997–1006. doi:10.1002/elps.201700375
- Zhang YS et al. (2017). Multisensor-integrated organs-on-chips platform for automated in situ monitoring. PNAS, 114(12), E2293–E2302. doi:10.1073/pnas.1612906114
- Vernetti L et al. (2017). Functional coupling of human microphysiology systems. Scientific Reports, 7, 42296. doi:10.1038/srep42296
- Esch EW et al. (2015). Organs-on-chips at the frontiers of drug discovery. Nature Reviews Drug Discovery, 14(4), 248–260. doi:10.1038/nrd4539
- Zheng F et al. (2021). Organ-on-a-chip systems: microengineering to biomimic living systems. Small, 17(7), 2004175. doi:10.1002/smll.202004175
